Vivos Therapeutics (VVOS) Non-Current Deffered Revenue (2019 - 2025)
Vivos Therapeutics' (VVOS) quarterly Non-Current Deffered Revenue came in at $1000.0 in Q3 2025, down 99.44% year-on-year from $178000.0 in Q3 2024, and down 80.0% on a QoQ basis from $5000.0 in Q2 2025.
Vivos Therapeutics (VVOS) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Non-Current Deffered Revenue data on file, last reported at $1000.0 in Q3 2025.
- On a quarterly basis, Non-Current Deffered Revenue fell 99.44% year-over-year to $1000.0 in Q3 2025; TTM through Sep 2025 was $1000.0, a 99.44% decrease from a year earlier, with the FY2024 full-year figure at $97000.0, down 66.44% from the prior year.
- Non-Current Deffered Revenue for Q3 2025 stood at $1000.0, down from $5000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for VVOS reached as high as $533000.0 in Q1 2024 and fell as low as $1000.0 in Q3 2025.
- Historically, Non-Current Deffered Revenue has averaged $236235.3 across 5 years, with a median of $250000.0 in 2023.
- Across the five-year window, Non-Current Deffered Revenue soared 158.04% in 2023 and sank 99.44% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $343000.0 in 2021, then plunged by 67.35% to $112000.0 in 2022, then surged by 158.04% to $289000.0 in 2023, then slumped by 66.44% to $97000.0 in 2024, then plunged by 98.97% to $1000.0 in 2025.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1000.0 in Q3 2025, $5000.0 in Q2 2025, and $22000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 512.79 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vivos Therapeutics | 3.62 Mn | 1.38 Mn | 3.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Dec 31, 2023 | 289,000.00 |
| Sep 30, 2023 | 240,000.00 |
| Jun 30, 2023 | 264,000.00 |
| Mar 31, 2023 | 250,000.00 |
| Dec 31, 2022 | 112,000.00 |
| Sep 30, 2022 | 180,000.00 |
| Jun 30, 2022 | 317,000.00 |
| Mar 31, 2022 | 375,000.00 |
| Dec 31, 2021 | 343,000.00 |
| Sep 30, 2021 | 360,000.00 |
| Jun 30, 2021 | 358,395.00 |
| Mar 31, 2021 | 212,076.00 |
| Dec 31, 2020 | 146,000.00 |